18 Apr 2017 07:59
4D pharma plc
(the "Company" or "4D")
Appointment of Joint Broker
4D pharma plc (AIM: DDDD), a pharmaceutical company focusing on the development of live biotherapeutics, announces that it has with immediate effect appointed Investec Bank plc as its joint corporate broker, to act alongside Zeus Capital Limited who remain the Company's Nominated Adviser and joint corporate broker.
For further information please contact:
4D | + 44 (0)113 895 0130 |
Duncan Peyton, Chief Executive Officer
| |
Zeus Capital Limited - Nomad and Joint Broker | |
Dan Bate | +44 (0) 161 831 1512 |
Dominic Wilson | +44 (0) 203 829 5000 |
Investec Bank plc - Joint Broker | +44 (0) 207 597 5970 |
Patrick Robb Daniel Adams Carlton Nelson |
About 4D
Founded in February 2014, 4D is a world leader in the development of live biotherapeutics, a novel and emerging class of drugs, defined by the FDA as biological products that contain a live organism, such as a bacteria, that is applicable to the prevention, treatment or cure of a disease. 4D has developed a proprietary platform, MicroRx, that rationally identifies novel bacteria that have a precise and evolved therapeutic effect. All of 4D's live biotherapeutic products are orally delivered single strains of bacteria that are naturally found in the healthy human gut. 4D currently has a pipeline of 13 preclinical programmes, covering disease areas such as rheumatoid arthritis, multiple sclerosis and cancer, and is currently conducting subject trials in Irritable Bowel Syndrome and Paediatric Crohn's Disease. The programmes in Paediatric Ulcerative Colitis and Paediatric Crohn's Disease have both been granted Orphan Drug Status by the FDA.